NM_000384.3:c.6936C>T

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_000384.3(APOB):​c.6936C>T​(p.Asp2312Asp) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.459 in 1,613,400 control chromosomes in the GnomAD database, including 181,005 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.38 ( 12426 hom., cov: 33)
Exomes 𝑓: 0.47 ( 168579 hom. )

Consequence

APOB
NM_000384.3 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:11

Conservation

PhyloP100: -0.386

Publications

37 publications found
Variant links:
Genes affected
APOB (HGNC:603): (apolipoprotein B) This gene product is the main apolipoprotein of chylomicrons and low density lipoproteins (LDL), and is the ligand for the LDL receptor. It occurs in plasma as two main isoforms, apoB-48 and apoB-100: the former is synthesized exclusively in the gut and the latter in the liver. The intestinal and the hepatic forms of apoB are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA->UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in this gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective apoB, diseases affecting plasma cholesterol and apoB levels. [provided by RefSeq, Dec 2019]
APOB Gene-Disease associations (from GenCC):
  • hypercholesterolemia, autosomal dominant, type B
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, G2P, Labcorp Genetics (formerly Invitae), ClinGen, Ambry Genetics
  • familial hypobetalipoproteinemia 1
    Inheritance: AR, AD, SD Classification: DEFINITIVE, STRONG Submitted by: PanelApp Australia, Labcorp Genetics (formerly Invitae), Genomics England PanelApp, ClinGen
  • homozygous familial hypercholesterolemia
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.91).
BP6
Variant 2-21009932-G-A is Benign according to our data. Variant chr2-21009932-G-A is described in ClinVar as Benign. ClinVar VariationId is 1169879.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-0.386 with no splicing effect.
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.495 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
APOBNM_000384.3 linkc.6936C>T p.Asp2312Asp synonymous_variant Exon 26 of 29 ENST00000233242.5 NP_000375.3 P04114Q7Z7Q0Q59HB3

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
APOBENST00000233242.5 linkc.6936C>T p.Asp2312Asp synonymous_variant Exon 26 of 29 1 NM_000384.3 ENSP00000233242.1 P04114

Frequencies

GnomAD3 genomes
AF:
0.381
AC:
57852
AN:
152002
Hom.:
12426
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.229
Gnomad AMI
AF:
0.533
Gnomad AMR
AF:
0.411
Gnomad ASJ
AF:
0.355
Gnomad EAS
AF:
0.0542
Gnomad SAS
AF:
0.239
Gnomad FIN
AF:
0.386
Gnomad MID
AF:
0.339
Gnomad NFE
AF:
0.500
Gnomad OTH
AF:
0.372
GnomAD2 exomes
AF:
0.388
AC:
97366
AN:
250982
AF XY:
0.390
show subpopulations
Gnomad AFR exome
AF:
0.220
Gnomad AMR exome
AF:
0.380
Gnomad ASJ exome
AF:
0.346
Gnomad EAS exome
AF:
0.0569
Gnomad FIN exome
AF:
0.404
Gnomad NFE exome
AF:
0.501
Gnomad OTH exome
AF:
0.419
GnomAD4 exome
AF:
0.467
AC:
682753
AN:
1461280
Hom.:
168579
Cov.:
43
AF XY:
0.461
AC XY:
335379
AN XY:
726938
show subpopulations
African (AFR)
AF:
0.209
AC:
6997
AN:
33458
American (AMR)
AF:
0.381
AC:
17038
AN:
44720
Ashkenazi Jewish (ASJ)
AF:
0.353
AC:
9214
AN:
26120
East Asian (EAS)
AF:
0.0527
AC:
2091
AN:
39654
South Asian (SAS)
AF:
0.267
AC:
23024
AN:
86238
European-Finnish (FIN)
AF:
0.411
AC:
21928
AN:
53368
Middle Eastern (MID)
AF:
0.334
AC:
1923
AN:
5762
European-Non Finnish (NFE)
AF:
0.517
AC:
574705
AN:
1111592
Other (OTH)
AF:
0.428
AC:
25833
AN:
60368
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.496
Heterozygous variant carriers
0
21481
42962
64444
85925
107406
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
16184
32368
48552
64736
80920
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.380
AC:
57857
AN:
152120
Hom.:
12426
Cov.:
33
AF XY:
0.371
AC XY:
27591
AN XY:
74332
show subpopulations
African (AFR)
AF:
0.229
AC:
9490
AN:
41512
American (AMR)
AF:
0.411
AC:
6284
AN:
15276
Ashkenazi Jewish (ASJ)
AF:
0.355
AC:
1230
AN:
3468
East Asian (EAS)
AF:
0.0541
AC:
280
AN:
5176
South Asian (SAS)
AF:
0.240
AC:
1157
AN:
4824
European-Finnish (FIN)
AF:
0.386
AC:
4082
AN:
10562
Middle Eastern (MID)
AF:
0.337
AC:
99
AN:
294
European-Non Finnish (NFE)
AF:
0.500
AC:
33967
AN:
67980
Other (OTH)
AF:
0.370
AC:
782
AN:
2116
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
1766
3532
5299
7065
8831
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
534
1068
1602
2136
2670
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.451
Hom.:
21579
Bravo
AF:
0.375
Asia WGS
AF:
0.164
AC:
575
AN:
3478
EpiCase
AF:
0.486
EpiControl
AF:
0.485

ClinVar

Significance: Benign
Submissions summary: Benign:11
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:3
-
Clinical Genetics, Academic Medical Center
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Apr 09, 2025
Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, Montreal Heart Institute
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Nov 30, 2024
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Familial hypercholesterolemia Benign:2
Sep 19, 2022
Cohesion Phenomics
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Jun 21, 2022
GENinCode PLC
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Hypercholesterolemia, autosomal dominant, type B;C4551990:Familial hypobetalipoproteinemia 1 Benign:1
Dec 16, 2021
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Hypercholesterolemia, autosomal dominant, type B Benign:1
Jul 14, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Familial hypobetalipoproteinemia 1 Benign:1
Jul 14, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Cardiovascular phenotype Benign:1
Dec 10, 2015
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.91
CADD
Benign
0.57
DANN
Benign
0.19
PhyloP100
-0.39
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs1041968; hg19: chr2-21232804; COSMIC: COSV51939479; API